Trials / Completed
CompletedNCT05366036
A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis
Post Marketing Surveillance Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Patients With Relapsing-Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 172 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the overall safety and efficacy of Tecfidera (Dimethyl Fumarate) as an oral treatment for Korean participants with relapsing-remitting multiple sclerosis (MS) under routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | This is a non-interventional study. |
Timeline
- Start date
- 2017-06-14
- Primary completion
- 2022-01-14
- Completion
- 2022-01-14
- First posted
- 2022-05-09
- Last updated
- 2022-05-09
Locations
20 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05366036. Inclusion in this directory is not an endorsement.